腹腔免疫化疗对晚期结肠癌癌性腹水患者IL-6及IL-10影响  

The Effects of Intraperitoneal Immunochemotherapy on IL - 6 and IL - 10 Level in Patients with Advanced Colon Cancer with Ascites

作　　者：金涌[1] 朱金水[1] 陈维雄[1] 孙群[1] 王如华[1] 陈尼维[1] 

机构地区：[1]上海市第六人民医院消化内科,上海200233

出　　处：《中国临床医学》2002年第5期519-520,共2页Chinese Journal of Clinical Medicine

摘　　要：目的:探讨腹腔内免疫化疗前后晚期结肠癌癌性腹水患者血清IL-6及IL-10水平的变化及其意义。方法:采用酶联免疫法测定治疗前、治疗后1周及治疗后4周患者外周血清中IL-6及IL-10水平,并与正常对照组比较。结果:晚期结肠癌癌性腹水患者血清IL-6及IL-10水平较正常组明显升高。腹腔内免疫化疗治疗晚期结肠癌癌性腹水患者1周后大部分患者外周血清中IL-6及IL-10水平有所下降。四周后所有患者的IL-6及IL-10均有下降。且第1周后IL-6及IL-10水平有否变化与免疫化疗是否有效有明显关系。结论:腹腔内免疫化疗是治疗晚期结肠癌癌性腹水较为有效的方法。同时,早期监测外周血清中IL-6及IL-10水平对腹腔内免疫化疗的疗效有预测功能。Objective: To study the effects of intraperitoneal immunochemotherapy on IL - 6 and IL - 10 level of advanced colon cancer patients with ascites. Methods: Before and after treatment, serum levels of IL -6 and IL -10 were observed by ELISA assay in 38 patients and compared with that in the control group. Results: The serum level of IL- 6 and IL- 10 of advanced colon cancer patients with ascites were higher than those of the control group. Serum level of IL - 6 and IL - 10 of most patients were decreased after first week of intraperitoneal immunochemotherapy and serum level of IL - 6 and IL - 10 were decreased in all patients after four weeks. And the change of serum level of IL - 6 and IL - 10 after first week treatment were correlated with effects of intraperitoeal immunochemotherapy. Conclusion: Intraperitoeal immunochemotherapy is an effective way for treat advanced colon cancer with ascites. Early monitoring serum level of IL - 6 and IL - 10 can predict the effect of intraperitoeal immunochemotherapy.

关 键 词：腹腔内免疫化疗 晚期结肠癌 癌性腹水 白介素6 白介素10 

分 类 号：R735.350.6[医药卫生—肿瘤]